PRTA vs. ABCL, MNKD, MIRM, BLTE, SYRE, COLL, LQDA, IRWD, PCRX, and GMTX
Should you be buying Prothena stock or one of its competitors? The main competitors of Prothena include AbCellera Biologics (ABCL), MannKind (MNKD), Mirum Pharmaceuticals (MIRM), Belite Bio (BLTE), Spyre Therapeutics (SYRE), Collegium Pharmaceutical (COLL), Liquidia (LQDA), Ironwood Pharmaceuticals (IRWD), Pacira BioSciences (PCRX), and Gemini Therapeutics (GMTX). These companies are all part of the "pharmaceutical preparations" industry.
AbCellera Biologics (NASDAQ:ABCL) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability.
AbCellera Biologics presently has a consensus target price of $15.86, indicating a potential upside of 293.48%. Prothena has a consensus target price of $68.14, indicating a potential upside of 197.18%. Given Prothena's stronger consensus rating and higher possible upside, equities research analysts clearly believe AbCellera Biologics is more favorable than Prothena.
In the previous week, AbCellera Biologics had 4 more articles in the media than Prothena. MarketBeat recorded 6 mentions for AbCellera Biologics and 2 mentions for Prothena. AbCellera Biologics' average media sentiment score of -0.13 beat Prothena's score of -0.14 indicating that Prothena is being referred to more favorably in the news media.
61.4% of AbCellera Biologics shares are held by institutional investors. Comparatively, 97.1% of Prothena shares are held by institutional investors. 32.5% of AbCellera Biologics shares are held by company insiders. Comparatively, 28.2% of Prothena shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Prothena received 548 more outperform votes than AbCellera Biologics when rated by MarketBeat users. However, 76.92% of users gave AbCellera Biologics an outperform vote while only 70.60% of users gave Prothena an outperform vote.
AbCellera Biologics has higher earnings, but lower revenue than Prothena. Prothena is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.
AbCellera Biologics has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500. Comparatively, Prothena has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500.
Prothena has a net margin of -160.91% compared to Prothena's net margin of -384.99%. Prothena's return on equity of -12.36% beat AbCellera Biologics' return on equity.
Summary
AbCellera Biologics beats Prothena on 13 of the 18 factors compared between the two stocks.
Get Prothena News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Prothena Competitors List
Related Companies and Tools
